OBJECTIVES: To examine the frequency and correlates of fatigue and its impact on physical and social functioning in patients with scleroderma, and to investigate whether fatigue mediates an association between pain and physical function. METHODS: One hundred and seven scleroderma patients attending an academic scleroderma specialty centre completed measures of fatigue, sleep, pain, depressive symptoms, and physical and social functioning. Patients had received a comprehensive clinical assessment with a diagnosis of limited or diffuse scleroderma from their attending rheumatologist. RESULTS: In this sample of scleroderma patients, 76% reported experiencing fatigue and 61% of these patients reported fatigue as one of their three most distressing symptoms. Patients endorsing greater pain had higher levels of self-reported fatigue, as did those reporting greater depression and poorer functioning. Multiple regression analyses indicated that global fatigue was a significant cross-sectional correlate of physical, but not social, functioning after controlling for depressive symptoms, level of education, poor sleep quality and disease subtype. However, global fatigue did not predict physical function when pain was included in the analyses. CONCLUSIONS: Our findings indicate that fatigue is common in scleroderma and that pain and fatigue are significant determinants of physical functioning for patients with limited and diffuse disease subtypes. Future research should investigate whether effective pain treatments reduce symptoms of fatigue, as well as identify other possible causes of fatigue in order to improve quality of life for scleroderma patients.
OBJECTIVES: To examine the frequency and correlates of fatigue and its impact on physical and social functioning in patients with scleroderma, and to investigate whether fatigue mediates an association between pain and physical function. METHODS: One hundred and seven sclerodermapatients attending an academic scleroderma specialty centre completed measures of fatigue, sleep, pain, depressive symptoms, and physical and social functioning. Patients had received a comprehensive clinical assessment with a diagnosis of limited or diffuse scleroderma from their attending rheumatologist. RESULTS: In this sample of sclerodermapatients, 76% reported experiencing fatigue and 61% of these patients reported fatigue as one of their three most distressing symptoms. Patients endorsing greater pain had higher levels of self-reported fatigue, as did those reporting greater depression and poorer functioning. Multiple regression analyses indicated that global fatigue was a significant cross-sectional correlate of physical, but not social, functioning after controlling for depressive symptoms, level of education, poor sleep quality and disease subtype. However, global fatigue did not predict physical function when pain was included in the analyses. CONCLUSIONS: Our findings indicate that fatigue is common in scleroderma and that pain and fatigue are significant determinants of physical functioning for patients with limited and diffuse disease subtypes. Future research should investigate whether effective pain treatments reduce symptoms of fatigue, as well as identify other possible causes of fatigue in order to improve quality of life for sclerodermapatients.
Authors: Astrid van Tubergen; Jolanda Coenen; Robert Landewé; Anneke Spoorenberg; Astrid Chorus; Annelies Boonen; Sjef van der Linden; Désirée van der Heijde Journal: Arthritis Rheum Date: 2002-02
Authors: Lisa M Benrud-Larson; Jennifer A Haythornthwaite; Leslie J Heinberg; Christy Boling; Jeffrey Reed; Barbara White; Fredrick M Wigley Journal: Pain Date: 2002-02 Impact factor: 6.961
Authors: Helen L Richards; Ariane L Herrick; Kerry Griffin; Petra D H Gwilliam; Jonathan Loukes; Dónal G Fortune Journal: Arthritis Rheum Date: 2003-10-15
Authors: Roozbeh Sharif; Maureen D Mayes; Perry M Nicassio; Emilio B Gonzalez; Hilda Draeger; Terry A McNearney; Rosa M Estrada-Y-Martin; Deepthi K Nair; John D Reveille; Frank C Arnett; Shervin Assassi Journal: Semin Arthritis Rheum Date: 2011-03-22 Impact factor: 5.532
Authors: Susan L Murphy; Anna L Kratz; Daniel Whibley; Janet L Poole; Dinesh Khanna Journal: Arthritis Care Res (Hoboken) Date: 2021-02-05 Impact factor: 4.794
Authors: Shervin Assassi; Astrud L Leyva; Maureen D Mayes; Roozbeh Sharif; Deepthi K Nair; Michael Fischbach; Ngan Nguyen; John D Reveille; Emilio B Gonzalez; Terry A McNearney Journal: PLoS One Date: 2011-10-14 Impact factor: 3.240